Commercial Climates Across Sleep

A deep dive into 50 segments of the sleep market from proven, mature categories to paradigm-shifting, moonshot ideas.

Commercial climates across sleep

Value is created when problems are solved. There are many sleep problems to be solved. There are also many problems that can be solved using sleep.

But this isn’t the whole story. All great businesses create value, but not all value creation creates great businesses. Great businesses require great markets, and great markets require advantageous commercial climates with favorable conditions prevailing from supplier to buyer. Vectors that coalesce to create an adverse or advantageous commercial climate include buyer awareness, unit economics, acquisition channels, distribution channels, competitor sets, complementary products, regulations, energy requirements, and technical infrastructure.

Sleep exhibits an array of categories at different stages of maturity with a wide spectrum of commercial climates. These range from proven categories with strong demand and many competitors all the way to sci-fi ideas still requiring major scientific advancements before commercial solutions can be built and sold. At Supermoon, we are tracking the evolution of commercial climates in real time across the full stack of sleep innovation.

This report groups 50 segments of the sleep market - product types, solution sets, and conceptual ideas - into five categories of market maturity. Although there are many segment to segment nuances, segments within each category generally share similar commercial climates, from buyer awareness levels to diversity of distribution channels to current states of scientific understanding.

Ultimately, sleep market innovation is still in its infancy. Proven segments are dominated by legacy incumbents with stale products. New entrants are beginning to capture net-new consumer spend by solving problems people are only beginning to realize they have. And at the frontier, basic science is uncovering both new problems and new solutions, creating new market segments still yet to emerge in the coming years.

Tier 1: Proven

Commercial climates for these segments are generally quite favorable. Consumers have shown willingness to pay, distribution channels from DTC to DME are well-established, and at least one company in each segment has achieved positive unit economics.

In this tier, value capture is more difficult than value creation. Many businesses compete for the same spend and segments face commoditization and price-competition.

Many of these segments are dominated by legacy incumbents with stale products. Beds & Bedding, CPAP, and OTC Aids are three of the largest segments in the entire sleep market and are controlled by household names like Mattress Firm / Tempur-Sealy (Somnigroup), Resmed, and Proctor & Gamble.

But high segment maturity offers day one upside to startups that can successfully navigate the increased competition. Opportunities include reformulation, novel delivery formats, unique branding, and multi-segment bundling.

Still, storm clouds are on the horizon for many of these segments. New entrants targeting new customer types with new solutions in less-mature sleep market categories are likely to capture market share from businesses in this category as their own commercial climate improves.

Tier 2: Growth

Segments in this category benefit from highly favorable economic, cultural, and technological trends. Many segments are growing quickly with at least one company in each demonstrating strong product-market fit.

Some segments still require high-touch buyer education - novel supplement ingredients, circadian productivity, and light therapy in particular. Yet commercial climates in this category are defined more by distribution, differentiation, go-to-market strategies, and defensible product wedges.

Crucially, segments in this category often benefit from lack of a segment leader. These segments are often fragmented with no dominant leader with outsized market share.

Opportunities include workflow integrations, clinical-consumer crossover plays, and ROI driven enterprise sales motions.

Tier 3: Emergent

Segments in this category straddle the threshold between science and commerce. Many of the products in this category are scientifically validated but narratively unfamiliar. Although buyers may be aware they have a problem worth solving, they either do not know that new solutions exist or do not believe these new solutions will actually solve their problem. Retailers, providers, and other distribution channels need to see end-user demand before buying in.

Identifying early-adopter cohorts is critical for companies in these segments. Perhaps it’s elite athletes and military special forces. Perhaps it’s struggling sleep provider groups seeking new revenue opportunities and new ways to cut costs.

Notably, many of the products in this category can be classified as “insights” - diagnostics, trackers, sensors, etc. These segments are key to unlocking future growth across the broader sleep market. Understanding sleep precedes solving sleep. Historically, breakthroughs in lab EEG & PSG testing empowered the CPAP market and today consumer wearables & HSTs are empowering novel interventions. Breakthroughs in anatomical profiling, circadian rhythm diagnostics, and consumer EEG can help potential buyers identify problems they face and incentivize demand for new solutions.

Value creation is the opportunity. Other opportunities include leveraging sleep data for adjacent specialities (cardiology, pulmonology), FDA approval for clinical validation, and design collaborations with popular consumer brands to reduce unfamiliarity.

Tier 4: Frontier

Commercial climates for segments in this category are generally undetermined. There may be massive latent demand or none at all. Qualitatively, many of these segments sound like big opportunities, if only.

Many of these segments suffer from not just passive buyer ignorance but active buyer skepticism. Value propositions sound too good to be true. Products often come with a host of caveats, indicated patient populations are outrageously narrow, and companies often fail to replicate laboratory performance when faced with real world conditions. There are outliers of course, but most products in this category just aren’t good enough yet.

The highest-conviction Tier 4 opportunity may be in novel therapeutics for sleep: GABAa agonists, orexin modulators, adenosine modulators, and other compounds designed to improve sleep architecture without the sedation and dependency profile of current options. Idorsia’s Quviviq and other new therapeutics show that the bench to bedside pipeline in sleep remains strong. Still, the segment is categorized as tier 4 due to significant pharmacological work that remains to be done, long clinical trial timelines, and perhaps most importantly, a historically conservative prescriber base of sleep docs and lack of a popular Hims/Ro-type DTC drug company in sleep, severely limiting end-patient awareness and distribution channels.

Productization of scientific research is the main opportunity in this category. Other opportunities include DTC drugs for sleep, initial go-to-market in more mature, non-sleep specialties (ex. oncology), combination therapies, and launching first with entertainment/fun features to sidestep buyer cynicism on clinical/scientific value props.

Tier 5: Sci-Fi

These are a set of scientific frontiers that, if crossed, would likely create markets — some of them larger than anything that currently exists.

The commercial climate for these segments is cold by every conventional measure: no buyers, no distribution channels, almost no regulatory frameworks, and no timelines. But basic science is progressing faster than most people realize and potential downstream commercial consequences are difficult to overstate.

Laboratories across the world are working on each of these ideas. Artificial hibernation / synthetic torpor is perhaps the most “advanced”; beyond the two company examples, we’ve met with a handful of stealth biotech and medtech companies inching closer to preclinical prototypes. Sleep compression - preserving the full restorative and memory-consolidation functions of sleep in 3–4 hours - and sleep replacement - “sleep without sleeping” - would unlock trillions of hours of consciousness with unimaginable consequences on life, labor, and the human experience.

Diversified market maturity

At Supermoon, we invest in companies across all five tiers of the market maturity spectrum and seek to build a portfolio with a diverse set of commercial climates. Ultimately, our task is to improve portfolio company legibility to customers and capital alike, transforming contrarian ideas into consensus. This suggests focus on tier 3 - emerging opportunities, where most products are scientifically validated but “narratively unfamiliar”. A decade from now, if you plot all of our initial investments across these five tiers I suspect you would see a normal distribution centered around tier 3.

Next deep dive will be on tech adoption in sleep.

---

Supermoon is a research-driven VC that invests in scientists, technologists, and creatives building the future of sleep and sleep-adjacent categories. We invest globally in pre-seed to Series A stage businesses across enterprise, consumer, and biotech. If you’re building in sleep or are interested in partnering with one of our portfolio companies, I’d love to chat. You can reach me on LinkedIn and Twitter, or email me directly at gj@supermooncapital.com.